# Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer

> **NCT00004199** · PHASE3 · COMPLETED · sponsor: **Pfizer**

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** prinomastat

## Key facts

- **NCT ID:** NCT00004199
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-03
- **Primary completion:** 2001-07
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2012-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004199, "Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00004199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*